Evaluation of the effect of eicosapentaenoic acid on plaques in human carotid arteries

Evaluation of the effect of eicosapentaenoic acid on plaques in human carotid arteries - EPA on CEA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004114

Enrollment

Registered

2010-08-27

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic plaques in carotid arteries.

Interventions

Administration of eicosapentate acid (1800mg/day) for 30 days. Administration of placebo for 30 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will undergo carotid endarterectomy in Tokushima University Hospital.

Exclusion criteria

Exclusion criteria: 1. Patients who have allergy for EPA. 2. Patients who have bleeding tendency. 3. Patients who had acute cerebral attack within six months. 4. Patients who has a history of peptic ulcer. 5. Patients whom doctors decided to exclude from this study.

Design outcomes

Primary

Measure	Time frame
Stabilization of plaques in human carotid arteries.	—

Countries

Japan

Contacts

Public ContactHirotsugu Yamada

Institute of Health Biosciences, the University of Tokushima Graduate School Department of Cardiovascular Medicine

yamada.md@gmail.com+81-88-633-7851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026